ORIGINAL ARTICLE

J Rhinol 2023;30(3):135-138 | https://doi.org/10.18787/jr.2023.00042

pISSN 1229-1498 / eISSN 2384-4361 www.j-rhinology.org

Extracellular Hsp70 Is Involved in the CXCL12/CXCR4 Pathway in Primary Human Nasal Epithelial Cells: A Preliminary Study

Seong Hee Kim, MD, Dong Young Kahng, MD, Kyung Soo Kim, MD, PhD, and Hyun Jin Min, MD, PhD

Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea

Background and Objectives: To date, no studies have been conducted on the interaction between extracellular heat shock protein 70 (Hsp70) and C-X-C chemokine receptor type 4 (CXCR4) in the upper airway. We aimed to evaluate the relationship between extracellular Hsp70 and CXCR4 and their role in the primary human nasal epithelium.

Methods: We cultured primary human nasal epithelial (HNE) cells in an air-liquid interface. Macrogen performed single-cell quantitative polymerase chain reaction and sequencing. We conducted western blot analysis for the CXCR4 and mitogen-activated protein kinase (MAPK) pathways.

Results: Extracellular Hsp70 treatment significantly increased the genetic expression and protein levels of CXCR4 in primary HNE cells. Phospho-ERK expression was increased by cotreatment with Hsp70 and CXCL12, but inhibited by pretreatment with AMD3100, a CXCR4 inhibitor. Pretreatment with an anti-Hsp70 antibody reduced phospho-ERK expression upregulation induced by cotreatment with Hsp70 and CXCL12.

Conclusion: Extracellular Hsp70 participates in the activation of the CXCR4-dependent downstream signaling pathway in HNE cells. Further studies should evaluate the extracellular Hsp70-CXCL12/CXCR4 axis and the role of its components in the development of inflammatory diseases.

Keywords: Hsp70; CXCL12; CXCR4; Nasal epithelium.

INTRODUCTION

Heat shock protein 70 (Hsp70), a molecular chaperone, participates in protein folding and the prevention of protein aggregation in the cytoplasm [1]. The presence of extracellular Hsp70 and its role as a damage-associated molecular pattern in various organs, including airways, have been reported [2,3]. Increased levels of extracellular Hsp70 have been detected in the serum of patients with asthma and in the bronchoalveolar lavage fluid of mice with allergic rhinitis (AR). Hsp70 affects the antigen activity of innate immune cells, and the chaperone activity of Hsp70 is involved in the pathogenesis of allergic airway disease through the regulation of unfolded

Received: June 9, 2023 Revised: July 4, 2023 Accepted: July 6, 2023

Address for correspondence: Hyun Jin Min, MD, PhD, Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of Korea Tel: +82-2-6299-1765, Fax: +82-2-825-1765, E-mail: jjinient@cau.ac.kr This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

protein responses induced by endoplasmic reticulum stress [2].

The chemokine receptor CXCR4 induces cellular migration, hematopoiesis, and cell homing. Neutrophils highly expressing CXCR4 are essential for the pathogenesis of the allergic airway response triggered by environmental factors [4]. Additionally, CXCR4 is involved in the pathogenesis of AR by interacting with its ligand, CXCL12 [5,6].

Lipopolysaccharides (LPS) are one of the most common pathogen-associated molecular patterns, and several LPS molecules can be integrated into receptor complexes to function as pattern recognition receptors. Hsp70 and CXCR4 have been identified as components of this receptor complex, suggesting their essential roles in initiating LPS-induced innate immune responses [7]. Additionally, Hsc/Hsp70-interacting protein (Hip) directly binds to CXCR4 and participates in CXCR4 internalization, which is important in the activation of mechanisms downstream of the CXCR4 pathway [8].

Since Hsp70 and CXCR4 constitute a common receptor complex, Hip directly interacts with CXCR4, and both extracellular Hsp70 and CXCR4 are important mediators in allergic airway diseases, we hypothesized that extracellular Hsp70

may be involved in the CXCR4-dependent signaling pathway. In this study, we primarily aimed to evaluate the relationship between extracellular Hsp70 and CXCR4 and their role in the primary human nasal epithelium.

METHODS

Experimental procedures using human nasal epithelial (HNE) cells were approved by the Institutional Review Board of Chung-Ang University Hospital (2020-002-405). Primary HNE cells were cultured in an air-liquid interface (ALI) environment as previously described [3]. Primary HNE cells from day 14 of the ALI culture were used in the experiments. Hsp70 (100 ng/mL; BD Biosciences, East Rutherford, NJ, USA) was added to the apical and basolateral culture media and maintained for the indicated durations. For single-cell quantitative polymerase chain reaction (PCR), RNA was extracted from two independent primary HNE cultures using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). RNasefree DNase (Qiagen, Hilden, Germany) was added to the extracts in accordance with the manufacturer's instructions. The extracted RNA samples were sequenced by Macrogen (Seoul, Republic of Korea; HiSeq 4000 instrument, Illumina Inc., San Diego, CA, USA), and sequencing results were analyzed. The raw reads from the sequencer were processed to remove lowquality and adapter sequences before analysis, and the processed reads were aligned to Homo sapiens (hg19) using HISAT v2.0.5 (https://daehwankimlab.github.io/hisat2/). Western blot analysis was performed using an anti-CXCR4 antibody, an anti-GAPDH antibody, and antibodies against the components of mitogen-activated protein kinase (MAPK) pathways (Cell Signaling Technology, Danvers, MA, USA) as previously described [3]. CXCL12 (250 ng/mL; R&D Systems, Minneapolis, MN, USA) was applied to the apical and basal culture media to activate the CXCL12/CXCR4 signaling pathway [9,10]. An anti-Hsp70 antibody (2 μ g/mL; Cell Signaling Technology) and AMD3100 (6 μ g/mL; Sigma-Aldrich, St. Louis, MO, USA) were used to inhibit the functions of extracellular Hsp70 and CXCR4, respectively. Western blotting was repeated at least thrice in independently cultured primary HNE cells.

Data were expressed as mean±standard deviation. Fold differences between groups were compared via the Mann–Whitney U test. Statistical significance was set at p<0.05. Data were statistically analyzed in GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA, USA).

RESULTS

Primary HNE cells were incubated with Hsp70 for 24 h, and single-cell RNA sequences were analyzed. Hsp70 treatment significantly changed the expression of various genes in primary HNE cells compared to the control (Table 1). Among them, *CXCR4* was the only target gene, whose expression was upregulated more than 3-fold by Hsp70 treatment, and it has been reported to be involved in the pathogenesis of allergic inflammation. Western blot analysis indicated that CXCR4 expression significantly increased after Hsp70 treatment (p<0.05) (Fig. 1).

We evaluated whether extracellular Hsp70 affected the downstream signaling pathway of CXCR4. We treated cells

Table 1. The 10 upregulated and 5 downregulated genes, including CXCR4, in Hsp70-treated HNE cells

| Gene symbol | Description | Fold change |
|-------------|--|-------------|
| CEBPB | CCAAT/enhancer binding protein beta | 9.002532 |
| SPRR2B | Small proline rich protein 2B | 5.419711 |
| EIF3C | Eukaryotic translation initiation factor 3 subunit C | 4.799372 |
| SERF1B | Small EDRK-rich factor 1B | 4.572111 |
| IGFBP3 | Insulin like growth factor binding protein 3 | 4.364950 |
| UPP1 | Uridine phosphorylase 1 | 4.161480 |
| RPS10-NUDT3 | RPS10-NUDT3 readthrough | 4.127389 |
| U2AF1 | U2 small nuclear RNA auxiliary factor 1 | 4.021925 |
| TBC1D3 | TBC1 domain family member 3 | 3.654779 |
| CHST2 | Carbohydrate sulfotransferase 2 | 3.488291 |
| CXCR4 | C-X-C motif chemokine receptor 4 | 3.191848 |
| U2AF1L5 | U2 small nuclear RNA auxiliary factor 1 like 5 | -23.263728 |
| MIR24-2 | MicroRNA 24-2 | -8.182278 |
| GLUL | Glutamate-ammonia ligase | -6.808756 |
| SORD2P | Sorbitol dehydrogenase 2, pseudogene | -6.362175 |
| FUT5 | Fucosyltransferase 5 | -6.256852 |

HNE, human nasal epithelial




Fig. 1. Administration of extracellular Hsp70 upregulated the expression of CXCR4 in primary HNE cells. A: Western blot showing the increased CXCR4 expression after Hsp70 treatment. B: Fold change in CXCR4 expression after Hsp70 treatment. HNE, human nasal epithelial. *p<0.05.




Fig. 2. Activation of the CXCL12/CXCR4 pathway by extracellular Hsp70 in primary HNE cells. A: p-ERK signaling was upregulated after cotreatment with Hsp70 and CXCL12, as revealed by western blotting. B: Pretreatment with an anti-Hsp70 antibody decreased the upregulation of p-ERK expression induced by cotreatment with Hsp70 and CXCL12, as demonstrated by western blotting. HNE, human nasal epithelial.

with Hsp70 with or without CXCL12, a well-identified CXCR4 agonist, and evaluated the downstream MAPK pathways via western blotting. We found that the expression of phospho-ERK was increased by cotreatment with Hsp70 and CXCL12 but inhibited by pretreatment with AMD3100, a CXCR4 inhibitor (Fig. 2A). Furthermore, pretreatment with the anti-Hsp70 antibody reduced the upregulation of phospho-ERK expression induced by cotreatment with Hsp70 and CXCL12 (Fig. 2B).

DISCUSSION

In this study, the extracellular administration of Hsp70 upregulated CXCR4 expression at gene and protein levels. Extracellular Hsp70 enhanced the downstream signaling pathway after CXCL12/CXCR4 binding, as demonstrated by increased phospho-ERK expression. These findings suggested that extracellular Hsp70 might be involved in the CXCL12/CXCR4 signal transduction pathway in primary HNE cells.

The pro-inflammatory and anti-inflammatory activities of Hsp70 have been identified in the upper airway. Hsp70 treatment prevents airway eosinophilia and allergen-induced cytokine release in mice with allergic asthma [11]. It also induces the production of interleukin (IL)-8 and tumor necrosis factor- α in human airway epithelial cells [12]. Although extracellular Hsp70 may be involved in the pathogenesis of AR [3], the underlying mechanisms are largely unexplored.

Previous studies demonstrated that the CXCL12/CXCR4 pathway plays a pivotal role in airway inflammation and airway hyperresponsiveness [5,6]. CXCR4 expression in the airway increases during the development of allergic airway disease, and CXCR4 inhibition reduces airway eosinophilia [6]. Furthermore, the inhibition of CXCL12/CXCR4 interaction decreases the level of Th2-associated cytokines, such as IL-4 and IL-5 [5].

On the basis of the current and past reports, we suggested that extracellular Hsp70 might participate in the CXCL12/CXCR4 signaling pathway in primary HNE cells. To the best of the authors' knowledge, this study is the first to evaluate the relationship between Hsp70 and the CXCR4 pathway in primary HNE cells. Given that extracellular Hsp70 and the CXCR4 pathway are important for the pathogenesis of AR, our preliminary study implies that future studies should focus on the interaction of Hsp70 and the CXCR4 pathway and its role in the development of upper airway diseases such as AR.

CXCR7 is a newly discovered receptor for CXCL12, and it has been found to be highly expressed in many tumor cells [13]. In a previous study, CXCR7 was reported to be expressed in lower airway epithelial cells, and CXCR7 played a role in regulating allergic airway inflammation in a mouse experiment

[14]. In our study, we did not find a significant change in genetic expression level of CXCR7 (data not shown). Future research on CXCR7 might be helpful in understanding the role of CXC12-mediated allergic airway inflammation.

There are several limitations to our study. First, our study was based on in vitro data using primary NHE cells. Therefore, in vivo experimental data, such as using an AR mouse model or human nasal tissues with or without the inhibition of extracellular Hsp70, are needed. Second, we did not further evaluate the downstream signaling pathway after CXCL12/CXCR4 axis activation. Further components of the downstream signaling pathway, such as NF-κB, need to be evaluated.

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Conflicts of Interest

Hyun Jin Min who is on the editorial board of the *Journal of Rhinology* was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.

Author Contributions

Conceptualization: Hyun Jin Min. Data curation: Seong Hee Kim. Formal analysis: Hyun Jin Min, Seong Hee Kim. Funding acquisition: Hyun Jin Min. Investigation: Kyung Soo Kim. Methodology: Dong Young Kahng. Project administration: Kyung Soo Kim. Supervision: Kyung Soo Kim. Validation: Hyun Jin Min. Writing—original draft: Seong Hee Kim, Hyun Jin Min. Writing—review & editing: Hyun Jin Min.

ORCID iDs

 Seong Hee Kim
 https://orcid.org/0000-0003-4492-2878

 Dong Young Kahng
 https://orcid.org/0009-0007-7141-4058

 Kyung Soo Kim
 https://orcid.org/0000-0003-2637-0555

 Hyun Jin Min
 https://orcid.org/0000-0003-3075-1350

Funding Statement

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT; 2022R1F1A1063720).

REFERENCES

 Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell 2006;125(3):443-51.

- Shevchenko M, Servuli E, Albakova Z, Kanevskiy L, Sapozhnikov A. The role of heat shock protein 70 kDa in asthma. J Asthma Allergy 2021:13:757-72.
- Min HJ, Kim KS, Yoon JH, Kim CH, Cho HJ. T-helper 2 cytokine-induced heat shock protein 70 secretion and its potential association with allergic rhinitis. Int Forum Allergy Rhinol 2017;7(5):530-5.
- Radermecker C, Sabatel C, Vanwinge C, Ruscitti C, Maréchal P, Perin F, et al. Locally instructed CXCR4^{hi} neutrophils trigger environmentdriven allergic asthma through the release of neutrophil extracellular traps. Nat Immunol 2019;20(11):1444-55.
- Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002;160(4):1353-60.
- 6) Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol 2000;165(1):499-508.
- Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002;115(Pt 12):2603-11.
- Fan GH, Yang W, Sai J, Richmond A. Hsc/Hsp70 interacting protein (hip) associates with CXCR2 and regulates the receptor signaling and trafficking. J Biol Chem 2002;277(8):6590-7.
- Chen H, Xu X, Teng J, Cheng S, Bunjhoo H, Cao Y, et al. CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2. Int J Clin Exp Pathol 2015;8(6):6700-7.
- 10) Wysoczynski M, Reca R, Ratajczak J, Kucia M, Shirvaikar N, Honczarenko M, et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005;105(1):40-8.
- 11) Shevchenko MA, Troyanova NI, Servuli EA, Bolkhovitina EL, Fedorina AS, Sapozhnikov AM. Study of immunomodulatory effects of extracellular HSP70 in a mouse model of allergic airway inflammation. Biochemistry (Mosc) 2016;81(11):1384-95.
- 12) Wheeler DS, Chase MA, Senft AP, Poynter SE, Wong HR, Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via toll-like receptor (TLR)-4. Respir Res 2009;10(1):31.
- 13) Xu D, Li R, Wu J, Jiang L, Zhong HA. Drug design targeting the CXCR4/ CXCR7/CXCL12 pathway. Curr Top Med Chem 2016;16(13):1441-51.
- 14) Chang HC, Huang PH, Syu FS, Hsieh CH, Chang SL, Lu J, et al. Critical involvement of atypical chemokine receptor CXCR7 in allergic airway inflammation. Immunology 2018;154(2):274-84.